{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T23:27:23Z","timestamp":1747178843822,"version":"3.40.5"},"reference-count":10,"publisher":"Informa UK Limited","issue":"4","funder":[{"name":"no funding to report"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Biological Therapy"],"published-print":{"date-parts":[[2022,4,3]]},"DOI":"10.1080\/14712598.2022.2035357","type":"journal-article","created":{"date-parts":[[2022,1,27]],"date-time":"2022-01-27T16:14:17Z","timestamp":1643300057000},"page":"445-447","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["ANDROMEDA: Dara-VCd for newly diagnosed AL amyloidosis: the next galaxy or a new standard of care?"],"prefix":"10.1080","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7978-1652","authenticated-orcid":false,"given":"James A.","family":"Davis","sequence":"first","affiliation":[{"name":"MUSC College of Pharmacy, Malignant Hematology, Medical University of South Carolina, MUSC Hollings Cancer Center, Charleston29425"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hamza","family":"Hashmi","sequence":"additional","affiliation":[{"name":"Hematology\/Oncology, Division of Malignant Hematology and Bone Marrow Transplant, Medical University of South Carolina, Charleston"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"key":"cit0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra023144"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2021.103435"},{"key":"cit0003","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2028631"},{"key":"cit0004","doi-asserted-by":"crossref","unstructured":"Comenzo R. Reduction in absolute involved free light chain and difference between involved and uninvolved free light chain is associated with prolonged major organ deterioration progression-free survival in patients with newly diagnosed AL amyloidosis receiving bortezomib, cyclophosphamide, and dexamethasone with or without daratumumab: results from andromeda. ASH; 2020 [cited 2021 Nov 21]. Available from https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper137582.html","DOI":"10.1182\/blood-2020-137582"},{"key":"cit0005","unstructured":"Sanchorawala V. Health-related quality of life in patients with AL amyloidosis treated with daratumumab, bortezomib, cyclophosphamide, and dexamethasone: results from the Phase 3 andromeda study. ASH; 2020 [cited 2021 Nov 21]. Available from: https:\/\/ash.confex.com\/ash\/2020\/webprogram\/Paper139438.html"},{"key":"cit0006","unstructured":"City of Hope Medical Center. A multicenter, open-label, single arm, Phase II study of daratumumab as consolidation\/maintenance therapy after autologous stem cell transplantation in patients with multiple myeloma. clinicaltrials.gov. Clinical Trial Registration NCT03346135; 2021 Feb 10 [cited 2021 Nov 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03346135"},{"key":"#cr-split#-cit0007.1","unstructured":"Daratumumab and Hyaluronidase. Lexi-drugs online [database on the Internet]. Hudson (OH): Lexicomp, Inc. 2022 [updated 2022 Jan 11"},{"key":"#cr-split#-cit0007.2","unstructured":"cited 2022 Jan 19]. Available from: http:\/\/online.lexi.com. Subscription required to view."},{"key":"cit0008","unstructured":"Weill Medical College of Cornell University. Daratumumab, pomalidomide, and dexamethasone (DPD) in relapsed\/refractory light chain amyloidosis patients previously exposed to daratumumab. clinicaltrials.gov. Clinical Trial Registration NCT04270175; 2021 Jun 23 [cited 2021 Nov 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04270175"},{"key":"cit0009","unstructured":"M.D. Anderson Cancer Center. A safety study of daratumumab, ixazomib, and dexamethasone in AL amyloidosis. clinicaltrials.gov. Clinical Trial Registration NCT03283917; 2021 Feb 12 [cited 2021 Nov 18]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03283917"}],"container-title":["Expert Opinion on Biological Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14712598.2022.2035357","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,18]],"date-time":"2022-03-18T15:42:22Z","timestamp":1647618142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14712598.2022.2035357"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4,3]]}},"alternative-id":["10.1080\/14712598.2022.2035357"],"URL":"https:\/\/doi.org\/10.1080\/14712598.2022.2035357","relation":{},"ISSN":["1471-2598","1744-7682"],"issn-type":[{"type":"print","value":"1471-2598"},{"type":"electronic","value":"1744-7682"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iebt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-12-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-01-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}